177 related articles for article (PubMed ID: 10093692)
41. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
42. Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer.
Sørensen JB; Stenbygaard LE; Dombernowsky P; Hansen HH
Ann Oncol; 1999 Sep; 10(9):1043-9. PubMed ID: 10572601
[TBL] [Abstract][Full Text] [Related]
43. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G
Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229
[TBL] [Abstract][Full Text] [Related]
44. Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer.
Zwitter M; Kovac V; Smrdel U; Kocijancic I; Segedin B; Vrankar M
Anticancer Drugs; 2005 Nov; 16(10):1129-34. PubMed ID: 16222156
[TBL] [Abstract][Full Text] [Related]
45. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer.
Chen YM; Perng RP; Yang KY; Liu TW; Tsai CM; Ming-Liu J; Whang-Peng J
Chest; 2000 Jun; 117(6):1583-9. PubMed ID: 10858387
[TBL] [Abstract][Full Text] [Related]
46. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer.
Abratt RP; Bezwoda WR; Goedhals L; Hacking DJ
J Clin Oncol; 1997 Feb; 15(2):744-9. PubMed ID: 9053500
[TBL] [Abstract][Full Text] [Related]
47. A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life.
Jassem J; Krzakowski M; Roszkowski K; Ramlau R; Słomiński JM; Szczesna A; Krawczyk K; Mozejko-Pastewka B; Lis J; Miracki K
Lung Cancer; 2002 Jan; 35(1):73-9. PubMed ID: 11750716
[TBL] [Abstract][Full Text] [Related]
48. Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Crul M; Schoemaker NE; Pluim D; Maliepaard M; Underberg RW; Schot M; Sparidans RW; Baas P; Beijnen JH; Van Zandwijk N; Schellens JH
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3526-33. PubMed ID: 14506138
[TBL] [Abstract][Full Text] [Related]
49. Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen.
Georgoulias V; Kourousis C; Kakolyris S; Androulakis N; Dimopoulos MA; Papadakis E; Kotsakis T; Vardakis N; Kalbakis K; Merambeliotakis N; Hatzidaki D
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-61-S12-66. PubMed ID: 9331124
[TBL] [Abstract][Full Text] [Related]
50. Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study.
Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Pacilio C; Gravina A; Caputi V; Botti G; Comella G
Ann Oncol; 1997 Oct; 8(10):1045-8. PubMed ID: 9402180
[TBL] [Abstract][Full Text] [Related]
51. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial.
Georgoulias V; Papadakis E; Alexopoulos A; Tsiafaki X; Rapti A; Veslemes M; Palamidas P; Vlachonikolis I;
Lancet; 2001 May; 357(9267):1478-84. PubMed ID: 11377599
[TBL] [Abstract][Full Text] [Related]
52. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.
Manegold C; van Zandwijk N; Szczesna A; Zatloukal P; Au JSK; Blasinska-Morawiec M; Serwatowski P; Krzakowski M; Jassem J; Tan EH; Benner RJ; Ingrosso A; Meech SJ; Readett D; Thatcher N
Ann Oncol; 2012 Jan; 23(1):72-77. PubMed ID: 21464154
[TBL] [Abstract][Full Text] [Related]
53. Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study.
Cappuzzo F; Selvaggi G; Gregorc V; Mazzoni F; Betti M; Rita Migliorino M; Novello S; Maestri A; De Marinis F; Darwish S; De Angelis V; Nelli F; Bartolini S; Scagliotti GV; Tonato M; Crinò L
Cancer; 2003 Jul; 98(1):128-34. PubMed ID: 12833465
[TBL] [Abstract][Full Text] [Related]
54. A phase II study with vinorelbine, gemcitabine and cisplatin in the treatment of patients with stage IIIb-IV non-small cell lung cancer (NSCLC).
Ginopoulos P; Mastronikolis NS; Giannios J; Karana A; Siabi V; Karvelas F; Rathossis S; Apostolopoulos N; Mastorakou A
Lung Cancer; 1999 Jan; 23(1):31-7. PubMed ID: 10100144
[TBL] [Abstract][Full Text] [Related]
55. Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma.
Shin SJ; Kim H; Baek JH; Ahn JJ; Jegal Y; Seo KW; Park CR; Shin JK; Jung JP; Kim JW; Cha HJ; Kwon WJ; Jeong AK; Noh YJ; Park JH; Min YJ
Lung Cancer; 2008 Apr; 60(1):83-91. PubMed ID: 18006180
[TBL] [Abstract][Full Text] [Related]
56. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project.
Crinò L; Scagliotti GV; Ricci S; De Marinis F; Rinaldi M; Gridelli C; Ceribelli A; Bianco R; Marangolo M; Di Costanzo F; Sassi M; Barni S; Ravaioli A; Adamo V; Portalone L; Cruciani G; Masotti A; Ferrara G; Gozzelino F; Tonato M
J Clin Oncol; 1999 Nov; 17(11):3522-30. PubMed ID: 10550150
[TBL] [Abstract][Full Text] [Related]
57. A novel biweekly schedule with cisplatin and gemcitabine in advanced non-small cell lung cancer.
López-Vivanco G; Fuente N; Barceló R; Rubio I; Muñoz A; Mañé JM; Pérez-Hoyos T; Viteri A; Ferreiro J
Int J Clin Pharmacol Res; 2003; 23(1):9-16. PubMed ID: 14621068
[TBL] [Abstract][Full Text] [Related]
58. Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose.
Shepherd FA; Burkes R; Cormier Y; Crump M; Feld R; Strack T; Schulz M
J Clin Oncol; 1996 May; 14(5):1656-62. PubMed ID: 8622085
[TBL] [Abstract][Full Text] [Related]
59. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
[TBL] [Abstract][Full Text] [Related]
60. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
Alberola V; Camps C; Provencio M; Isla D; Rosell R; Vadell C; Bover I; Ruiz-Casado A; Azagra P; Jiménez U; González-Larriba JL; Diz P; Cardenal F; Artal A; Carrato A; Morales S; Sanchez JJ; de las Peñas R; Felip E; López-Vivanco G;
J Clin Oncol; 2003 Sep; 21(17):3207-13. PubMed ID: 12947054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
